LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing ...
Lurie Cancer Center Completes Dosing of First Patient with LIXTE’s LB-100 in Combination with GSK’s Immunotherapy Dostarlimab --PASADENA, ...